Zevra Therapeutics, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zevra Therapeutics, Inc.

Verrica Pharmaceuticals, Inc.

XOMA Corp.

Emergent BioSolutions, Inc.

Zomedica Corp.

Fusion Pharmaceuticals, Inc.

Gossamer Bio, Inc.

Omeros Corp.

Merrimack Pharmaceuticals, Inc.

Sagimet Biosciences, Inc.

Tenaya Therapeutics, Inc.

Why is Zevra Therapeutics, Inc. ?

With a growth in Operating Profit of 66.31%, the company declared Outstanding results in Sep 25

NET PROFIT(HY) Higher at USD 137.3 MM
ROCE(HY) Highest at 34.81%
NET SALES(Q) Highest at USD 26.06 MM

With ROE of 72.30%, it has a very attractive valuation with a 4.35 Price to Book Value

Over the past year, while the stock has generated a return of 15.81%, its profits have risen by 207.3% ; the PEG ratio of the company is 0

High Institutional Holdings at 85.04%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
Their stake has increased by 7.81% over the previous quarter.

Market Beating performance in long term as well as near term

Along with generating 15.81% returns in the last 1 year, the stock has outperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you buy?

Overall Portfolio exposure to Zevra Therapeutics, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Zevra Therapeutics, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Zevra Therapeutics, Inc.

17.6%

1.68

59.04%

S&P 500

16.12%

0.77

19.29%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

46.99%

EBIT Growth (5y)

-217.63%

EBIT to Interest (avg)

-14.46

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.05

Sales to Capital Employed (avg)

0.28

Tax Ratio

22.06%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

85.04%

ROCE (avg)

10.83%

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.35

EV to EBIT

-15.25

EV to EBITDA

-18.70

EV to Capital Employed

-96.17

EV to Sales

5.23

PEG Ratio

0.03

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

72.30%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

Mildly Bearish

RSI

No Signal

Bollinger Bands

Sideways

Bullish

Moving Averages

Mildly Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

37What is working for the Company

NET PROFIT(HY)

Higher at USD 137.3 MM

ROCE(HY)

Highest at 34.81%

NET SALES(Q)

Highest at USD 26.06 MM

RAW MATERIAL COST(Y)

Fallen by -290.27% (YoY

CASH AND EQV(HY)

Highest at USD 402.12 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 33.85 times

DEBTORS TURNOVER RATIO(HY)

Highest at 6.85 times

OPERATING PROFIT(Q)

Highest at USD 4.54 MM

OPERATING PROFIT MARGIN(Q)

Highest at 17.4 %

-6What is not working for the Company

PRE-TAX PROFIT(Q)

At USD 4.4 MM has Fallen at -78.85%

NET PROFIT(Q)

At USD 4.84 MM has Fallen at -69.22%

Here's what is working for Zevra Therapeutics, Inc.

Net Sales

At USD 26.06 MM has Grown at 68.09%

over average net sales of the previous four periods of USD 15.51 MM

MOJO Watch

Near term sales trend is extremely positive

Net Sales (USD MM)

Net Sales

Highest at USD 26.06 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (USD MM)

Operating Profit

Highest at USD 4.54 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at 17.4 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

Cash and Eqv

Highest at USD 402.12 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio

Highest at 33.85 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Debtors Turnover Ratio

Highest at 6.85 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost

Fallen by -290.27% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zevra Therapeutics, Inc.

Pre-Tax Profit

At USD 4.4 MM has Fallen at -78.85%

over average net sales of the previous four periods of USD 20.83 MM

MOJO Watch

Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit

At USD 4.84 MM has Fallen at -69.22%

over average net sales of the previous four periods of USD 15.72 MM

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)